TW200902551A - Polypeptides, antibody variable domains & antagonists - Google Patents

Polypeptides, antibody variable domains & antagonists Download PDF

Info

Publication number
TW200902551A
TW200902551A TW097121296A TW97121296A TW200902551A TW 200902551 A TW200902551 A TW 200902551A TW 097121296 A TW097121296 A TW 097121296A TW 97121296 A TW97121296 A TW 97121296A TW 200902551 A TW200902551 A TW 200902551A
Authority
TW
Taiwan
Prior art keywords
domlh
sequence
variable region
antagonist
amino acid
Prior art date
Application number
TW097121296A
Other languages
English (en)
Chinese (zh)
Inventor
Armin Sepp
Laurent Stephane Anne Therese Jespers
Malgorzata Pupecka
Ian Tomlinson
Carolyn Enever
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0724331.4A external-priority patent/GB0724331D0/en
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of TW200902551A publication Critical patent/TW200902551A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/544Mucosal route to the airways
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
TW097121296A 2007-06-06 2008-06-06 Polypeptides, antibody variable domains & antagonists TW200902551A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93363207P 2007-06-06 2007-06-06
GBGB0724331.4A GB0724331D0 (en) 2007-12-13 2007-12-13 Compositions for pulmonary delivery

Publications (1)

Publication Number Publication Date
TW200902551A true TW200902551A (en) 2009-01-16

Family

ID=39791116

Family Applications (6)

Application Number Title Priority Date Filing Date
TW097121296A TW200902551A (en) 2007-06-06 2008-06-06 Polypeptides, antibody variable domains & antagonists
TW097121268A TW200911831A (en) 2007-06-06 2008-06-06 Polypeptides, antibody variable domains & antagonists
TW097121295A TW200911832A (en) 2007-06-06 2008-06-06 Polypeptides, antibody variable domains & antagonists
TW097121280A TW200907128A (en) 2007-06-06 2008-06-06 Methods for selecting protease resistant polypeptides
TW097121301A TW200918088A (en) 2007-06-06 2008-06-06 Polypeptides, antibody variable domains & antagonists
TW097121265A TW200911834A (en) 2007-06-06 2008-06-06 Polypeptides, antibody variable domains & antagonists

Family Applications After (5)

Application Number Title Priority Date Filing Date
TW097121268A TW200911831A (en) 2007-06-06 2008-06-06 Polypeptides, antibody variable domains & antagonists
TW097121295A TW200911832A (en) 2007-06-06 2008-06-06 Polypeptides, antibody variable domains & antagonists
TW097121280A TW200907128A (en) 2007-06-06 2008-06-06 Methods for selecting protease resistant polypeptides
TW097121301A TW200918088A (en) 2007-06-06 2008-06-06 Polypeptides, antibody variable domains & antagonists
TW097121265A TW200911834A (en) 2007-06-06 2008-06-06 Polypeptides, antibody variable domains & antagonists

Country Status (31)

Country Link
US (5) US20100247515A1 (enExample)
EP (5) EP2162467B1 (enExample)
JP (3) JP5325211B2 (enExample)
KR (4) KR20100018040A (enExample)
CN (4) CN101883788A (enExample)
AR (3) AR066850A1 (enExample)
AU (4) AU2008259590A1 (enExample)
BR (3) BRPI0812795C1 (enExample)
CA (6) CA2688433A1 (enExample)
CL (3) CL2008001673A1 (enExample)
CO (2) CO6251321A2 (enExample)
CR (2) CR11195A (enExample)
CY (1) CY1116762T1 (enExample)
DK (1) DK2162467T3 (enExample)
DO (1) DOP2009000268A (enExample)
EA (5) EA200901494A1 (enExample)
ES (1) ES2546943T3 (enExample)
HR (1) HRP20151024T1 (enExample)
HU (1) HUE025899T2 (enExample)
IL (2) IL201398A0 (enExample)
MA (2) MA31403B1 (enExample)
MX (4) MX2009013137A (enExample)
NZ (1) NZ581372A (enExample)
PE (3) PE20090322A1 (enExample)
PL (1) PL2162467T3 (enExample)
PT (1) PT2162467E (enExample)
SG (2) SG182141A1 (enExample)
SI (1) SI2162467T1 (enExample)
TW (6) TW200902551A (enExample)
WO (3) WO2008149150A2 (enExample)
ZA (1) ZA200908470B (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP3613767A1 (en) 2005-05-18 2020-02-26 Ablynx N.V. Improved nanobodiestm against tumor cecrosis factor-alpha
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
NZ580530A (en) * 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
EP2220115A2 (en) * 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
HRP20241467T1 (hr) 2008-06-25 2025-01-03 Novartis Ag Stabilna i topljiva protutijela koja inhibiraju vegf
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102224169A (zh) * 2008-11-26 2011-10-19 葛兰素集团有限公司 多肽、抗体可变结构域和拮抗剂
WO2010081787A1 (en) 2009-01-14 2010-07-22 Domantis Limited IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
KR20110119806A (ko) * 2009-02-19 2011-11-02 글락소 그룹 리미티드 개선된 항­tnfr1 폴리펩티드,항체 가변 도메인 및 길항제
KR101819754B1 (ko) * 2009-02-19 2018-01-18 글락소 그룹 리미티드 개선된 항-혈청 알부민 결합 변이체
ES2654929T3 (es) 2009-02-19 2018-02-15 Glaxo Group Limited Variantes de unión de anti-albúmina de suero mejoradas
JP2012518398A (ja) 2009-02-24 2012-08-16 グラクソ グループ リミテッド 抗原結合性構築物
US20120107330A1 (en) 2009-07-16 2012-05-03 Adriaan Allart Stoop Antagonists, uses & methods for partially inhibiting tnfr1
CN102574914A (zh) 2009-07-16 2012-07-11 葛兰素集团有限公司 改进的抗血清清蛋白结合性单可变区
US20110223149A1 (en) * 2009-10-14 2011-09-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
PH12012500826A1 (en) 2009-10-27 2013-01-07 Glaxo Group Ltd Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
AU2011254559B2 (en) * 2010-05-20 2014-09-04 Glaxo Group Limited Improved anti-serum albumin binding variants
WO2012020143A1 (en) 2010-08-13 2012-02-16 Glaxo Group Limited Improved anti-serum albumin binding variants
AU2011290797A1 (en) * 2010-08-20 2013-04-11 Glaxosmithkline Intellectual Property Development Limited Improved anti-serum albumin binding variants
KR101871008B1 (ko) 2010-09-16 2018-06-25 발리오팜 아게 항-huTNFR1 항체
JP2014501515A (ja) 2010-12-01 2014-01-23 グラクソ グループ リミテッド 改良された抗血清アルブミン結合単一可変ドメイン
WO2012104227A1 (en) 2011-02-02 2012-08-09 Glaxo Group Limited Novel antigen binding proteins
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
SG10201601621PA (en) 2011-06-28 2016-04-28 Inhibrx Llc Serpin fusion polypeptides and methods of use thereof
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
WO2013014208A2 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited Antigen binding constructs
ES2813432T3 (es) * 2011-08-17 2021-03-23 Glaxo Group Ltd Proteínas y péptidos modificados
GB2497138A (en) * 2011-12-02 2013-06-05 Randox Lab Ltd Biomarkers for stroke and stroke subtype diagnosis.
RS62509B1 (sr) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
AU2014211438B2 (en) * 2013-01-31 2017-02-02 Glaxo Group Limited Method of producing a protein
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
NZ744185A (en) 2015-12-30 2025-09-26 Kodiak Sciences Inc Antibodies and conjugates thereof
GB201617622D0 (en) * 2016-10-18 2016-11-30 VIB VZW and Universiteit Gent Means and methods to treat inflammation
RU2625010C1 (ru) * 2016-11-10 2017-07-11 Илья Петрович Приколаб Экспрессионный плазмидный вектор для экспрессии активной формы TNFR1-Fc и способ получения рекомбинантного белка
AU2017364817B2 (en) 2016-11-28 2023-11-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
BR112019008265A2 (pt) 2016-11-28 2019-07-09 Chugai Pharmaceutical Co Ltd molécula de ligação ao ligante cuja atividade de li-gação ao ligante é ajustável
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
EP3703689A1 (en) * 2017-11-01 2020-09-09 Allogene Therapeutics, Inc. Modified caspase-9 polypeptides and methods of use thereof
JP7482630B2 (ja) 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
JP7414736B2 (ja) 2018-05-30 2024-01-16 中外製薬株式会社 アグリカン結合ドメインおよび運搬部分を含むポリペプチド
EP3802831A4 (en) * 2018-05-30 2022-07-27 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising il-1r1 binding domain and carrying moiety
EP3623798B1 (de) * 2018-09-13 2021-11-03 Euroimmun Medizinische Labordiagnostika AG Verfahren und vorrichtung zum erfassen und darstellen eines immunfluoreszenzbildes einer biologischen probe
EP3870331B1 (en) * 2018-10-25 2025-07-23 F. Hoffmann-La Roche AG Modification of antibody fcrn binding
WO2020089051A1 (en) 2018-10-29 2020-05-07 F. Hoffmann-La Roche Ag Antibody formulation
MY205459A (en) 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
CN111454366B (zh) * 2019-01-21 2023-06-16 中国科学院深圳先进技术研究院 一种融合蛋白及其应用
JP7315967B2 (ja) * 2019-01-31 2023-07-27 積水メディカル株式会社 生物学的試料中の遊離aimの免疫学的分析方法及び測定キット
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7473398B2 (ja) * 2020-05-28 2024-04-23 シスメックス株式会社 キャリブレータ、複合体、及びIgA凝集体を測定する方法
IL300930A (en) * 2020-08-27 2023-04-01 Enosi Therapeutics Corp Methods and compositions for the treatment of autoimmune diseases and cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CN115181751A (zh) * 2021-04-02 2022-10-14 苏州博腾生物制药有限公司 靶向白蛋白的嵌合抗原受体及其使用方法
CN114657162B (zh) * 2022-03-04 2023-06-16 华南理工大学 一种具有血管内皮细胞保护功能的抗氧化五肽及其应用
CN115112704B (zh) * 2022-06-21 2025-07-15 中特检验集团有限公司 一种光热发电有机热载体热稳定性检测方法
AR129879A1 (es) 2022-07-08 2024-10-09 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof
CN119909772B (zh) * 2025-04-01 2025-06-20 安徽一帆新材料科技有限公司 用于净水的再生阴树脂及其制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
WO1992010092A1 (en) 1990-12-06 1992-06-25 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
WO1999002671A1 (en) 1997-07-07 1999-01-21 Medical Research Council In vitro sorting method
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
ATE380865T1 (de) 1998-05-13 2007-12-15 Domantis Ltd Phagen-display-selektionssystem für korrekt gefaltete proteine
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
EP1252319A2 (en) 2000-02-03 2002-10-30 Domantis Limited Combinatorial protein domains
AU2001238076A1 (en) 2000-02-11 2001-08-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US7115415B2 (en) * 2000-09-15 2006-10-03 Genentech, Inc. PRO9821 nucleic acids
EP2027874B1 (en) 2000-11-28 2013-10-16 Medimmune, Inc. Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2004003019A2 (en) 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
CA2496834C (en) 2002-09-06 2014-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
ES2315664T3 (es) * 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
PL1729795T3 (pl) 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
EP2172553A1 (en) 2004-03-24 2010-04-07 Domantis Limited Gas1 universal leader
WO2006047325A1 (en) * 2004-10-21 2006-05-04 Genentech, Inc. Method for treating intraocular neovascular diseases
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
JP2008521870A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド 抗il−1r1単一ドメイン抗体および治療使用
JP2009519011A (ja) 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン1受容体1型に結合する非競合ドメイン抗体フォーマット
US20080311111A1 (en) 2005-12-01 2008-12-18 Drew Philip D Competitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1
LT2068889T (lt) 2006-08-10 2020-02-10 Roy C. Levitt Anakinra, naudojama bronchiolito obliteranso sindromo gydymui
US20100129354A1 (en) * 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
NZ580530A (en) 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists

Also Published As

Publication number Publication date
CA2688447C (en) 2016-11-08
PL2162467T3 (pl) 2015-12-31
EP2746291B1 (en) 2019-08-14
WO2008149148A3 (en) 2009-04-02
EP2164867A2 (en) 2010-03-24
JP2010530364A (ja) 2010-09-09
CL2008001673A1 (es) 2008-11-21
EA200901494A1 (ru) 2010-06-30
KR20100040841A (ko) 2010-04-21
IL202204A0 (en) 2010-06-16
PE20090763A1 (es) 2009-07-10
EP2746290A2 (en) 2014-06-25
CA2688433A1 (en) 2008-12-11
EP2746291A2 (en) 2014-06-25
EA018723B1 (ru) 2013-10-30
EA200901300A1 (ru) 2010-06-30
ZA200908470B (en) 2011-02-23
KR101604274B1 (ko) 2016-03-17
IL201398A0 (en) 2010-05-31
HK1138022A1 (en) 2010-08-13
CA2683791A1 (en) 2008-12-11
AU2008259516A1 (en) 2008-12-11
CN104311663B (zh) 2018-11-02
CN101778865A (zh) 2010-07-14
HUE025899T2 (en) 2016-05-30
SG182141A1 (en) 2012-07-30
CR11195A (es) 2010-05-24
MA31403B1 (fr) 2010-05-03
PE20090323A1 (es) 2009-04-20
CN101778865B (zh) 2016-11-09
CA2688456A1 (en) 2008-12-11
CN101883788A (zh) 2010-11-10
MX2009013138A (es) 2010-04-30
TW200911831A (en) 2009-03-16
US20090148437A1 (en) 2009-06-11
MX2009013211A (es) 2010-04-09
TW200907128A (en) 2009-02-16
US20110256122A1 (en) 2011-10-20
WO2008149149A3 (en) 2009-04-02
DK2162467T3 (en) 2015-08-24
CA2683823A1 (en) 2008-12-11
CY1116762T1 (el) 2017-03-15
JP5444215B2 (ja) 2014-03-19
MA31668B1 (fr) 2010-09-01
EA201100546A1 (ru) 2011-12-30
KR20100041746A (ko) 2010-04-22
NZ581372A (en) 2012-02-24
CR11194A (es) 2010-06-28
TW200911832A (en) 2009-03-16
SI2162467T1 (sl) 2015-11-30
AR066850A1 (es) 2009-09-16
EP2746290A3 (en) 2014-09-10
BRPI0812795B1 (pt) 2019-12-03
BRPI0812795A2 (pt) 2014-12-02
EP2162468A2 (en) 2010-03-17
AR066848A1 (es) 2009-09-16
US20100266616A1 (en) 2010-10-21
BRPI0813899A2 (pt) 2019-09-24
JP2010529841A (ja) 2010-09-02
CN101802004A (zh) 2010-08-11
CN104311663A (zh) 2015-01-28
CO6251321A2 (es) 2011-02-21
JP2010530220A (ja) 2010-09-09
AU2008259514A1 (en) 2008-12-11
EA200901495A1 (ru) 2010-10-29
WO2008149148A2 (en) 2008-12-11
TW200918088A (en) 2009-05-01
EP2162467A2 (en) 2010-03-17
JP5325211B2 (ja) 2013-10-23
WO2008149150A3 (en) 2009-06-25
EA018129B1 (ru) 2013-05-30
BRPI0812795B8 (pt) 2020-01-28
EA200901491A1 (ru) 2010-08-30
AU2008259514B2 (en) 2014-05-15
WO2008149149A2 (en) 2008-12-11
CA2688447A1 (en) 2008-12-11
CO6251322A2 (es) 2011-02-21
BRPI0812268A2 (pt) 2019-09-10
AU2008259515A1 (en) 2008-12-11
BRPI0812795C1 (pt) 2021-05-25
CL2008001676A1 (es) 2008-11-21
US20100247515A1 (en) 2010-09-30
CL2008001674A1 (es) 2008-11-21
CA2688434A1 (en) 2008-12-11
AU2008259590A1 (en) 2008-12-11
ES2546943T3 (es) 2015-09-30
PE20090322A1 (es) 2009-04-20
TW200911834A (en) 2009-03-16
EP2162467B1 (en) 2015-07-22
MX2009013137A (es) 2010-04-30
US20120134982A1 (en) 2012-05-31
HRP20151024T1 (hr) 2015-11-06
EP2746291A3 (en) 2014-09-03
WO2008149150A2 (en) 2008-12-11
PT2162467E (pt) 2015-10-29
SG182151A1 (en) 2012-07-30
AR066847A1 (es) 2009-09-16
DOP2009000268A (es) 2010-02-28
US8398979B2 (en) 2013-03-19
EP2746290B1 (en) 2019-08-14
MX2009012967A (es) 2010-04-01
KR20100018040A (ko) 2010-02-16
KR20100021642A (ko) 2010-02-25

Similar Documents

Publication Publication Date Title
TW200902551A (en) Polypeptides, antibody variable domains & antagonists
AU2008259513B2 (en) Polypeptides, antibody variable domains and antagonists
US9562090B2 (en) Polypeptides, antibody variable domains and antagonists